Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sitravatinib · MGCD-516, MG-516

Small molecule · Inhibitor of MET, AXL and KIT · developed by Mirati Therapeutics

Phase 3 Most advanced trial (none active)

BMY Developer

1 Registered trials

What is Sitravatinib?

Sitravatinib is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor that binds to and inhibits multiple RTKs including MET, AXL, KIT, MER, DDR2, VEGFR types 1-3, PDGFR family members, RET, TRK, and Eph family kinases. It is studied in metastatic non-squamous non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MGCD-516, MG-516, MG-91516
Drug type: Small molecule
Targets: MET, AXL, KIT, MERTK, DDR2, VEGFR (FLT1)
Mechanism: Inhibitor of MET, AXL and KIT
Pathways: signal transduction, tumor cell proliferation inhibition
Therapy area: Oncology
Developer: Mirati Therapeutics Inc. (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: CWG62Q1VTB

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03906071	Phase 3	Metastatic Non-Squamous Non-Small Cell Lung Cancer	Terminated	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Other drugs acting on MET / AXL / KIT / MERTK / DDR2 / FLT1

Midostaurin FDA approved Nintedanib FDA approved Pexidartinib FDA approved Regorafenib FDA approved Sunitinib FDA approved Telisotuzumab Vedotin FDA approved Tepotinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 Barzolvolimab Phase 3 Bezuclastinib Phase 3 Briquilimab Phase 1/2 CDX 0158 Phase 1

More from Mirati Therapeutics

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Sitravatinib

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z